Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer - CA025-006

Updated: 9 September, 2020   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 2


  • Gender(s)

  • 18+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
Active Comparator: Arm A
Drug: Nab-paclitaxel Drug: Onivyde Drug: Irinotecan Hydrochloride Drug: Gemcitabine Drug: Leucovorin Drug: Fluorouracil
Experimental: Arm B
Biological: Nivolumab Biological: Cabiralizumab
Experimental: Arm C
Biological: Cabiralizumab Drug: Nab-paclitaxel Biological: Nivolumab Drug: Gemcitabine
Experimental: Arm D
Biological: Cabiralizumab Biological: Nivolumab Drug: Fluorouracil Drug: Oxaliplatin Drug: Leucovorin

Key Eligibility Criteria

Inclusion Criteria: - Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy - ECOG Performance status 0-1 - Adequate organ functions - Measurable disease Exclusion Criteria: - Suspected or known CNS metastasis - Participants with active, known, or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - Prior exposure to selected immune cell-modulating antibody regimens

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com